Archives
-
5-Azacytidine: DNMT Biology to Leukemia Strategy
2026-09-25
5-Azacytidine connects DNMT inhibition with gene reactivation, but translational studies need to separate epigenetic target engagement from broader cellular effects. This article uses recent leukemia research to outline a rigorous, mechanism-led strategy for applying 5-AzaC in cancer models.
-
FITC-Concanavalin A: Workflow and QC Guide
2026-09-25
FITC-Concanavalin A is a fluorescent lectin conjugate for detecting accessible α-D-glucose- and α-D-mannose-containing structures on cell surfaces and in tissues by microscopy or flow cytometry. Use it for carbohydrate-focused assays, not as a probe for non-carbohydrate targets; follow the specified light-protected, refrigerated storage conditions.
-
5-Azacytidine: From Epigenetic Editing to Cell Fate
2026-09-24
5-Azacytidine is more than a DNA demethylation tool: its DNMT-trapping chemistry can connect epigenetic perturbation to DNA-damage signaling and cell death. Explore the multiple myeloma evidence, practical study-design considerations, and translational limits that matter when taking 5-AzaC from bench models toward therapeutic hypotheses.
-
EZH2 Inhibition and 5-Azacytidine in PTEN-Deficient GBM
2026-09-24
A 2025 study reports that PTEN deficiency weakens the ERV–MAVS–type I interferon pathway in glioblastoma, supporting an immunosuppressive tumor environment. In the study, 5-azacytidine alone did not restore this response, whereas combining it with EZH2 inhibition reduced H3K27me3, increased ERV activity, and strengthened antitumor immunity—an important mechanistic rationale, not yet evidence of clinical benefit.
-
MPS IVA Cartilage Pathology and Lysosomal Exocytosis
2026-09-23
A zebrafish study links GALNS deficiency in mucopolysaccharidosis type IVA to enhanced lysosomal exocytosis, altered glycosaminoglycan abundance, and reduced TGFβ/BMP signaling in developing cartilage. The findings extend disease models beyond substrate storage while showing that the relationship between exocytosis, protease activity, and growth-factor signaling differs across lysosomal disorders.
-
JNJ-26481585 (Quisinostat) Assay Guide
2026-09-23
A scenario-based guide to using JNJ-26481585 (Quisinostat), SKU A4090, in cell viability, proliferation, and apoptosis workflows. It connects HDAC biology with practical stock preparation, orthogonal readouts, resistance studies, and evidence-based product selection.
-
Tivozanib (AV-951): VEGFR Inhibition Guide
2026-09-22
Tivozanib, also called AV-951, is a selective VEGFR tyrosine kinase inhibitor for renal cell carcinoma research and anti-angiogenic therapy studies. Its VEGFR-2 potency, clinical evidence, and assay-specific limitations make it useful for mechanism-focused oncology workflows.
-
Phosphotungstic Acid Negative Stain: Image to Insight
2026-09-22
Phosphotungstic Acid Negative Stain Solution (2%) supports high-contrast electron microscopy of viruses, macromolecules, and cells. This guide explains how morphology imaging can strengthen, but not replace, mechanistic assays of coronavirus glycan-targeting research.
-
5-Azacytidine Reprograms Dormant Cancer Cells
2026-09-21
The 2023 Cell Reports study shows that 5-Azacytidine combined with retinoic acid can reprogram disseminated cancer cells into a stable, non-proliferative state rather than simply eliminating them. The work links this effect to restoration of TGF-β–SMAD4 signaling and provides a framework for studying metastasis suppression through dormancy control.
-
Lambda Protein Phosphatase for BMAL1 Assays
2026-09-21
Lambda Protein Phosphatase enables a more rigorous BMAL1 phosphorylation workflow by separating phosphatase-sensitive regulation from antibody artifacts and phase-separation assay variability. Learn how λ-PPase supports causal, mechanism-aware circadian protein studies.
-
5-Azacytidine Workflows for Epigenetic Assays
2026-09-20
Build more reproducible DNA demethylation, gene-reactivation, and cancer-cell response assays with 5-Azacytidine. This guide connects practical dose–time design with a new PTEN-deficient glioblastoma viral-mimicry study, helping researchers distinguish DNMT-dependent effects from general cytotoxicity.
-
Structure-Guided Proteomimetics Block SARS-CoV-2 Entry
2026-09-19
The reference study introduces a structure-guided proteomimetic strategy for disrupting the difficult SARS-CoV-2 S-RBD/hACE2 protein–protein interaction. By combining stabilized α-helical and cyclic β-sheet mimetics, the lead construct 28 inhibited pseudovirus entry and showed lung epithelial stability with low permeability, supporting further investigation of localized antiviral delivery.
-
InstaBlue Protein Stain Solution Protocol
2026-09-18
InstaBlue Protein Stain Solution provides rapid Coomassie Brilliant Blue visualization of protein bands in polyacrylamide gels without fixation, washing, or destaining. It is suited to routine protein electrophoresis analysis and mass spectrometry workflows, but its stated 5 ng detection level should not be treated as a universal quantitative limit or a replacement for a validated protein quantification assay.
-
5-Azacytidine: From DNMT Trapping to Translation
2026-09-18
5-Azacytidine is more than a DNA demethylation agent: its covalent DNMT trapping can connect epigenetic reprogramming with ATR-mediated DNA damage and apoptosis. This thought-leadership guide translates the mechanism into experimental design, multiple myeloma research, leukemia modeling, and combination-development strategy.
-
DiscoveryProbe Natural Product Library Plus for HTS
2026-09-17
The DiscoveryProbe Natural Product Library Plus connects broad natural-product diversity with a disciplined path from biochemical hit discovery to cell-based validation. Its pre-dissolved format and quality controls make it especially useful for target-led assays, phenotypic profiling, and mechanism-aware antiparasitic drug discovery.